vs
Side-by-side financial comparison of SOLESENCE, INC. (SLSN) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
SOLESENCE, INC. is the larger business by last-quarter revenue ($12.5M vs $5.0M, roughly 2.5× cbdMD, Inc.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -5.6%, a 6.9% gap on every dollar of revenue. On growth, SOLESENCE, INC. posted the faster year-over-year revenue change (-0.7% vs -1.9%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs 7.1%).
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
SLSN vs YCBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $5.0M |
| Net Profit | $163.0K | $-283.1K |
| Gross Margin | 27.5% | 59.8% |
| Operating Margin | 1.5% | -5.7% |
| Net Margin | 1.3% | -5.6% |
| Revenue YoY | -0.7% | -1.9% |
| Net Profit YoY | 129.2% | -1975.7% |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.5M | $5.0M | ||
| Q3 25 | $14.6M | $4.7M | ||
| Q2 25 | $20.4M | $4.6M | ||
| Q1 25 | $14.6M | $4.7M | ||
| Q4 24 | $12.6M | $5.1M | ||
| Q3 24 | $16.9M | $4.6M | ||
| Q2 24 | $13.0M | $5.2M | ||
| Q1 24 | $9.9M | $4.4M |
| Q4 25 | $163.0K | $-283.1K | ||
| Q3 25 | $-1.1M | $-680.0K | ||
| Q2 25 | $2.7M | $-895.3K | ||
| Q1 25 | $80.0K | $-480.8K | ||
| Q4 24 | $-559.0K | $15.1K | ||
| Q3 24 | $3.0M | $-152.8K | ||
| Q2 24 | $856.0K | $459.7K | ||
| Q1 24 | $893.0K | $-3.0M |
| Q4 25 | 27.5% | 59.8% | ||
| Q3 25 | 23.1% | 58.8% | ||
| Q2 25 | 28.9% | 61.5% | ||
| Q1 25 | 23.1% | 62.3% | ||
| Q4 24 | 22.0% | 66.5% | ||
| Q3 24 | 36.2% | 53.9% | ||
| Q2 24 | 28.7% | 65.8% | ||
| Q1 24 | 36.3% | 59.0% |
| Q4 25 | 1.5% | -5.7% | ||
| Q3 25 | -5.4% | -14.5% | ||
| Q2 25 | 9.4% | -19.6% | ||
| Q1 25 | 1.8% | -10.2% | ||
| Q4 24 | -1.8% | -1.7% | ||
| Q3 24 | 19.0% | -6.9% | ||
| Q2 24 | 8.0% | -7.4% | ||
| Q1 24 | 11.3% | -35.4% |
| Q4 25 | 1.3% | -5.6% | ||
| Q3 25 | -7.7% | -14.4% | ||
| Q2 25 | 13.1% | -19.4% | ||
| Q1 25 | 0.5% | -10.1% | ||
| Q4 24 | -4.4% | 0.3% | ||
| Q3 24 | 18.1% | -3.4% | ||
| Q2 24 | 6.6% | 8.9% | ||
| Q1 24 | 9.0% | -68.8% |
| Q4 25 | $0.00 | — | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $0.04 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.04 | — | ||
| Q2 24 | $0.01 | $-0.15 | ||
| Q1 24 | $0.02 | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3M | $3.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $17.6M | $9.0M |
| Total Assets | $50.1M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3M | $3.4M | ||
| Q3 25 | $429.0K | $2.3M | ||
| Q2 25 | $4.1M | $1.1M | ||
| Q1 25 | $1.8M | $1.8M | ||
| Q4 24 | $1.4M | $2.0M | ||
| Q3 24 | $2.9M | $2.5M | ||
| Q2 24 | $2.4M | $2.4M | ||
| Q1 24 | $2.0M | $2.1M |
| Q4 25 | $17.6M | $9.0M | ||
| Q3 25 | $17.2M | $7.2M | ||
| Q2 25 | $18.2M | $6.1M | ||
| Q1 25 | $15.2M | $665.8K | ||
| Q4 24 | $14.9M | $1.8M | ||
| Q3 24 | $15.2M | $2.0M | ||
| Q2 24 | $11.9M | $3.0M | ||
| Q1 24 | $5.0M | $3.1M |
| Q4 25 | $50.1M | $11.8M | ||
| Q3 25 | $54.0M | $10.4M | ||
| Q2 25 | $60.0M | $9.9M | ||
| Q1 25 | $57.0M | $10.9M | ||
| Q4 24 | $50.0M | $11.5M | ||
| Q3 24 | $48.0M | $10.6M | ||
| Q2 24 | $40.8M | $13.8M | ||
| Q1 24 | $38.5M | $14.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-812.5K |
| Free Cash FlowOCF − Capex | — | $-977.3K |
| FCF MarginFCF / Revenue | — | -19.5% |
| Capex IntensityCapex / Revenue | — | 3.3% |
| Cash ConversionOCF / Net Profit | 11.16× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $-812.5K | ||
| Q3 25 | $-2.5M | $-240.7K | ||
| Q2 25 | $-654.0K | $-704.2K | ||
| Q1 25 | $-7.2M | $-189.5K | ||
| Q4 24 | $2.2M | $-317.9K | ||
| Q3 24 | $4.2M | $167.4K | ||
| Q2 24 | $-565.0K | $289.8K | ||
| Q1 24 | $-3.9M | $-704.1K |
| Q4 25 | — | $-977.3K | ||
| Q3 25 | — | $-243.6K | ||
| Q2 25 | — | $-705.7K | ||
| Q1 25 | — | $-205.0K | ||
| Q4 24 | $-404.0K | $-482.3K | ||
| Q3 24 | $2.8M | $157.4K | ||
| Q2 24 | $-1.0M | — | ||
| Q1 24 | $-3.9M | $-708.7K |
| Q4 25 | — | -19.5% | ||
| Q3 25 | — | -5.2% | ||
| Q2 25 | — | -15.3% | ||
| Q1 25 | — | -4.3% | ||
| Q4 24 | -3.2% | -9.4% | ||
| Q3 24 | 16.6% | 3.5% | ||
| Q2 24 | -8.0% | — | ||
| Q1 24 | -39.9% | -16.2% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | 20.6% | 3.2% | ||
| Q3 24 | 8.3% | 0.2% | ||
| Q2 24 | 3.7% | 0.0% | ||
| Q1 24 | 0.9% | 0.1% |
| Q4 25 | 11.16× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.25× | — | ||
| Q1 25 | -90.26× | — | ||
| Q4 24 | — | -21.06× | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | -0.66× | 0.63× | ||
| Q1 24 | -4.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SLSN
Segment breakdown not available.
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
